Amon Asgharpour, MD
Transplant Hepatology · New York, NYNPI 1720221278
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Intercept Pharmaceuticals, Inc. accounts for 75.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $37,505 and has fallen 90.7% since, to $3,499 in 2025. Among transplant hepatology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $766.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$44K
- Novo Nordisk$6K
- Gilead$4K
- Madrigal Pharmaceuticals$2K
- Bristol Myers Squibb$2K
- Fujifilm Healthcare Americas Corporation$77
- plus $260 from 8 others
Across 108 payments — averaging $6181.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$210K
- Intercept Pharmaceuticals, Inc.$167K
- Takeda Pharmaceuticals U.S.A., Inc.$159K
- Gilead$93K
- GSK$36K
- Eli Lilly$3K
- plus $578 from 1 others
What the payments were for
- Consulting fees$17,86331%
- Speaking & faculty fees$33,99958%
- Travel & lodging$4,0917%
- Food & beverage$2,2834%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 38 | $43,990 |
| Novo Nordisk | 5 | $5,755 |
| Gilead | 14 | $3,906 |
| Madrigal Pharmaceuticals | 3 | $2,403 |
| Bristol Myers Squibb | 4 | $1,845 |
| Fujifilm Healthcare Americas Corporation | 1 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $70 |
| Pfizer | 1 | $40 |
| Boston Scientific | 2 | $39 |
| Merck | 1 | $36 |
| Merit Medical Systems Inc | 2 | $27 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
| Conmed Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCALIVA$4,395
- RESMETIROM$1,935
- CC-90001$1,845
- REZDIFFRA$468
How this compares
$58,236 in reported general payments places this provider in the 90th percentile of 36 transplant hepatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 14 | $57,872 |
| Tacrolimus | 28 | $5,123 |
| Spironolactone | 19 | $357 |
| Pantoprazole Sodium | 25 | $208 |
| Furosemide | 25 | $162 |
| Hydroxyzine Hcl | 15 | $46 |
Paid to pharmacies, not to this prescriber.
Other transplant hepatology in New York
- Nikolaos PyrsopoulosNew York$251K
- James ParkNew York$81K
- Giuseppe CullaroNew York$50K
- Julia WattacherilNew York$37K
- Gene ImNew York$15K
- Elizabeth VernaNew York$11K
- Rajani SharmaNew York$11K
- Annmarie LiapakisNew York$10K
- Alyson FoxNew York$10K
- Linda LawNew York$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.